Why President Trump Is Wrong about Trans-Pacific Partnership Agreement

McDonnell Boehnen Hulbert & Berghoff LLP
Contact

On Monday, President Trump made good on one of his signature campaign promises and notified the other twelve countries (Australia, Brunei, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore, and Vietnam) considering ratifying the Trans-Pacific Partnership (TPP) Agreement that the United States was withdrawing from the treaty and he would not ask Congress to ratify it.  The President's stated reasons for doing so, reiterated many times last year, was that the treaty was bad for American workers and part of a pattern of trade agreements that had taken jobs from U.S. workers and encouraged businesses to offshore capital and production capacity in favor of countries where labor was cheaper than in the U.S.

Regardless of whether these arguments have merit, the President was wrong to withdraw from the TPP, which was generally favorable to American interests and would have had no effect on the U.S. job market.  This is because the provisions of the treaty favored American innovators, specifically biotechnology and pharmaceutical companies but all creative industries (including film, recording artists, and writers, among others) whose efforts are not offshored.  Indeed, as the U.S. Trade Representative has documented in his Special 301 Report every year (see "U.S. Trade Representative Issues 2016 Special 301 Report"), counterfeiting of creative works (videos, phonorecords and CDs, videogames, feature films, and the like) work a considerable hardship on creative companies in the U.S. that employ millions of workers.  These folks are not just the creative talent (with whom the President may have a contentious relationship) but all the grips, camera operators, electricians, special effects people, and others that are listed seemingly ad infinitum at the end of every movie, even ones without apparent special effects.  It also includes all the support staff, caterers, tutors for young actors, crowd control people, and even lawyers involved in the creative process.  Counterfeiting is a global problem and the TPP, like most trade agreements, either contained provisions directed at limiting the effects of such counterfeiting or set out a framework for signatory countries to do so.

For pharmaceuticals, similar albeit more pernicious consequences can be expected to arise from the President's decision.  Pharmaceutical companies act from a global perspective, so that events happening abroad influence their strategies worldwide.  There are two possible outcomes for the TPP now that the U.S. has withdrawn.  The first is that the remaining countries fail to ratify the agreement (or that the number who do fall under the requirement that signatories make up 34% of global GDP) and the status quo remains.  But that status quo is that there is no market exclusivity for biologic drugs in many of these countries.  Accordingly, U.S. biopharma companies will need to rely on patent protection and enforcement country-by-country to protect their investment in providing drugs to these countries.  This is a much more expensive proposition that the regulatory exclusivity (a minimum of 8 years of market exclusivity) provided for in the TPP.  Without this protection, provided by signatory governments preventing biosimilar drugs to be marketed until the exclusivity term expired, biosimilar competition will be immediate, or as soon as possible.  Companies like Samsung's Bioepsis biosimilar subsidiary, and others, can be expected to enter the biosimilar market as soon as their development pathway will allow.  Alternatively, the remaining countries may still ratify the treaty; in that case the benefits to biopharma companies in those countries would still accrue.  But if the TPP is ratified in the remaining countries, it may behoove U.S. biologic drug companies to partner with or resource their biologic drug production to an affiliate in a TPP country in order to reap the 8-year market exclusivity benefits under the treaty.  This will not improve prospects for jobs in the U.S. or bring jobs home; indeed, it will reduce the need to produce in the U.S. these drugs for sale in the TPP countries.

Another possibility is that China (which has voiced an interest in being involved in the agreement) may ask to be allowed to enter the TPP and in America's absence it will be the Chinese and not the Americans that will be the dominant power among TPP countries.  This is unlikely to inure to our benefit and while consistent with a broad retrenchment into a more isolationist, "America First" stance such an outcome will mean that Chinese (or Indian, or Russian, or Brazilian) interests rather than American interests will be at the global forefront.

The fact is that economic realities are what is behind American job loss.  This happens for reasons that know no national borders, such as automation, which has taken jobs from automobile and other factory workers worldwide.  There are also national and regional effects, such as the cheaper costs of manual labor and disregard for proscriptions against child labor in some countries, factors against which Americans are unlikely to be prepared to compete.  American influence, such as the pressure put on companies like Apple and Nike, can have some effect in ameliorating the extent to which practices like child labor are utilized.  But this influence is diminished not strengthened by an American abandonment of its leadership role in the world.

The Trump administration has plans to "renegotiate" the North American Free Trade Agreement (NAFTA), despite indications that the treaty has been a net positive for the U.S. economy.  We may also expect that other trade agreements, like the Trans-Atlantic Trade and Investment Partnership (TTIP) and the Trade in Services Agreement (TiSA), are also at risk.  It is logical to expect such an outcome, insofar as you cannot have an international trade agreement based on an "America First" policy; other countries are unlikely to agree to the kind of one-sided agreement this would require.  Like President Bush's "Coalition of the Willing" during the Iraq War, only those countries dependent on the U.S. would agree to be involved and those are not our most profitable trading partners.

The fact is that global economics preclude the kind of repatriation of certain jobs to the U.S. that is the basis for the President's policies.  America's advantage with regard to the rest of the world rests on the stability of our institutions and the creativity of our people.  The TPP promoted our creative advantage, but the isolationist policies behind our withdrawal do nothing to expand American competitiveness and influence in the world.  Withdrawal from the TPP was a mistake, and one we will likely come to regret when none of the purported benefits of walking away from the treaty come to pass.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Written by:

McDonnell Boehnen Hulbert & Berghoff LLP
Contact
more
less

McDonnell Boehnen Hulbert & Berghoff LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.